Skeletal Muscle Regeneration from Differentiating Pluripotent Stem Cells
分化多能干细胞的骨骼肌再生
基本信息
- 批准号:8926353
- 负责人:
- 金额:$ 33.44万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2008
- 资助国家:美国
- 起止时间:2008-09-25 至 2019-07-31
- 项目状态:已结题
- 来源:
- 关键词:
项目摘要
DESCRIPTION (provided by applicant): Pluripotent stem cells (ES and iPS cells) have the ability to self-renew and to differentiate into multiple lineages in vitro. This makes these cells powerful tool to study early embryonic developmental pathways and to generate specific cell populations for regenerative medicine and disease investigation. Supported by R01 AR055299, our research group has pioneered methods to derive skeletal myogenic cells from mouse and human pluripotent ES and iPS cells. Until our work, studies in this area were rare since skeletal myogenic differentiation is extremely inefficient during in vitro differentiation. We reasoned that
because in vitro systems do not recapitulate neural tube or notochord development, and indeed do not produce structures resembling somites, that the inducing signals that properly pattern paraxial mesoderm were absent. We have overcome this roadblock by activating the myogenic program through transient induction of Pax3 or Pax7 during early mesoderm development. This approach allows for the in vitro generation of large quantities of early embryonic skeletal myogenic progenitors. Transplantation of these cells into dystrophic mice results in myofiber and satellite cell engraftment that is accompanied by improvement in muscle force generation. This renewal application builds on the advances we have brought to the field over the past 5 years and evolves from these into 3 areas: i) understanding the molecular regulation of the embryonic myogenic program by Pax3, ii) investigating the long-term regenerative capacity of human pluripotent donor-derived satellite cells as well as their transcriptional profiling in comparison to in vitro generated myogenic progenitors, and iii) using myotubes from patient-specific pluripotent cells to biochemically and functionally model DMD/BMD pathology and its reversal by therapeutic delivery of dystrophin mini-genes.
描述(由申请人提供):多能干细胞(ES和IPS细胞)具有自我更新并在体外分化为多个谱系的能力。这使这些细胞具有强大的工具来研究早期的胚胎发育途径并生成特定的细胞群来进行再生医学和疾病研究。在R01 AR055299的支持下,我们的研究小组采用了从小鼠和人类多能ES和IPS细胞中得出骨骼肌细胞的方法。在我们的工作之前,在该领域的研究很少,因为在体外分化过程中骨骼肌分化效率极低。我们认为这一点
因为体外系统不会概括神经管或脊索发育,并且确实不会产生类似于情节的结构,因此缺乏适当模拟近地胚层的诱导信号。我们通过在中胚层发育期间通过对PAX3或PAX7的短暂诱导来激活肌源程序来克服这一障碍。这种方法允许体外生成大量早期胚胎骨骼肌祖细胞。将这些细胞移植到营养不良的小鼠中会导致肌纤维和卫星细胞植入,并伴随着肌肉力产生的改善。这种更新的应用是基于我们在过去的5年中带入该领域的进步,并将这些申请从这些方面发展为3个领域:i)理解PAX3的分子调节,PAX3,ii)研究人类多元化供体卫星细胞的长期再生能力,并研究了其在比较中,并在其转录的生成中进行了培训,并在Quartientien pription中使用了II,并在Quartipition中使用了II,并在Vetro中进行了培训,并在Vetro sentrientien pription Is and Introic sentory heentii sentory sentory sogen controcy y in comploty introk y in corbality sento sentory,从患者特异性多能细胞到生化和功能上DMD/BMD病理学的肌管及其通过治疗性肌营养不良蛋白迷你生成来逆转。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

暂无数据
数据更新时间:2024-06-01
Rita C. R. Perling...的其他基金
Targeting Dystroglycanopathies using Pluripotent-derived Myogenic Progenitors
使用多能源性肌源性祖细胞靶向肌营养不良症
- 批准号:1056137510561375
- 财政年份:2023
- 资助金额:$ 33.44万$ 33.44万
- 项目类别:
Disease Modeling of Skeletaland Cardiac Muscle in DMD/BMD using Patient-Specific iPS Cells
使用患者特异性 iPS 细胞对 DMD/BMD 中的骨骼肌和心肌进行疾病建模
- 批准号:1058603510586035
- 财政年份:2022
- 资助金额:$ 33.44万$ 33.44万
- 项目类别:
Disease Modeling of Skeletaland Cardiac Muscle in DMD/BMD using Patient-Specific iPS Cells
使用患者特异性 iPS 细胞对 DMD/BMD 中的骨骼肌和心肌进行疾病建模
- 批准号:1039055310390553
- 财政年份:2022
- 资助金额:$ 33.44万$ 33.44万
- 项目类别:
Skeletal Muscle Regeneration from Pluripotent Stem Cells
多能干细胞的骨骼肌再生
- 批准号:1041382610413826
- 财政年份:2021
- 资助金额:$ 33.44万$ 33.44万
- 项目类别:
Skeletal Muscle Regeneration from Pluripotent Stem Cells
多能干细胞的骨骼肌再生
- 批准号:1063310710633107
- 财政年份:2021
- 资助金额:$ 33.44万$ 33.44万
- 项目类别:
Targeting Dystroglycanopathies using Pluripotent-derived Myogenic Progenitors
使用多能源性肌源性祖细胞靶向肌营养不良症
- 批准号:94826999482699
- 财政年份:2017
- 资助金额:$ 33.44万$ 33.44万
- 项目类别:
Examining the Therapeutic Potential of iPS cells in Duchenne Muscular Dystrophy
检查 iPS 细胞在杜氏肌营养不良症中的治疗潜力
- 批准号:78089407808940
- 财政年份:2010
- 资助金额:$ 33.44万$ 33.44万
- 项目类别:
Skeletal Muscle Regeneration from Differentiating Embryonic Stem Cells
分化胚胎干细胞的骨骼肌再生
- 批准号:81263798126379
- 财政年份:2008
- 资助金额:$ 33.44万$ 33.44万
- 项目类别:
Skeletal Muscle Regeneration from Differentiating Embryonic Stem Cells
分化胚胎干细胞的骨骼肌再生
- 批准号:83221958322195
- 财政年份:2008
- 资助金额:$ 33.44万$ 33.44万
- 项目类别:
Skeletal Muscle Regeneration from Differentiating Embryonic Stem Cells
分化胚胎干细胞的骨骼肌再生
- 批准号:76929257692925
- 财政年份:2008
- 资助金额:$ 33.44万$ 33.44万
- 项目类别:
相似国自然基金
定向金属结合区域的倒捻子素类PDE4抑制剂:类药性优化及抗肺纤维化作用研究
- 批准号:22277019
- 批准年份:2022
- 资助金额:54.00 万元
- 项目类别:面上项目
定向金属结合区域的倒捻子素类PDE4抑制剂:类药性优化及抗肺纤维化作用研究
- 批准号:
- 批准年份:2022
- 资助金额:54 万元
- 项目类别:面上项目
高光谱遥感与地面观测数据结合的区域甘蔗糖分估算研究
- 批准号:42105175
- 批准年份:2021
- 资助金额:24.00 万元
- 项目类别:青年科学基金项目
ERβ结合区域遗传变异与结直肠癌发病风险的机制研究
- 批准号:
- 批准年份:2020
- 资助金额:57 万元
- 项目类别:面上项目
基于“区域资源高效协同机制”作用的医养结合养老社区中医疗功能空间配置研究
- 批准号:
- 批准年份:2020
- 资助金额:58 万元
- 项目类别:面上项目
相似海外基金
Anti-flavivirus B cell response analysis to aid vaccine design
抗黄病毒 B 细胞反应分析有助于疫苗设计
- 批准号:1063632910636329
- 财政年份:2023
- 资助金额:$ 33.44万$ 33.44万
- 项目类别:
The Role of Glycosyl Ceramides in Heart Failure and Recovery
糖基神经酰胺在心力衰竭和恢复中的作用
- 批准号:1064487410644874
- 财政年份:2023
- 资助金额:$ 33.44万$ 33.44万
- 项目类别:
Elucidating the role of DCAF7 on hematopoietic stem cell maintenance
阐明 DCAF7 对造血干细胞维持的作用
- 批准号:1078544310785443
- 财政年份:2023
- 资助金额:$ 33.44万$ 33.44万
- 项目类别:
Bivalent degraders of the understudied transcription factor TBXT for the rare cancer chordoma
正在研究的罕见癌症脊索瘤转录因子 TBXT 的二价降解剂
- 批准号:1072582110725821
- 财政年份:2023
- 资助金额:$ 33.44万$ 33.44万
- 项目类别:
The cardiovascular consequences of sleep apnea plus COPD (Overlap syndrome)
睡眠呼吸暂停加慢性阻塞性肺病(重叠综合征)对心血管的影响
- 批准号:1073338410733384
- 财政年份:2023
- 资助金额:$ 33.44万$ 33.44万
- 项目类别: